Hematology News

The FDA approved the enzyme replacement therapy Adzynma for the prophylactic or on-demand treatment of adults and pediatric patients with congenital thrombotic thrombocytopenic purpura, a rare blood clotting disorder.

Individuals with severe sickle cell disease showed willingness to accept the risks associated with emerging gene therapy treatments, according to survey results published in Blood Advances.

Male patients, Black patients and rural area residents with pulmonary embolism had poorer age-adjusted mortality rates than their respective opposing demographics, according to results published in Annals of the American Thoracic Society.

An FDA panel appeared comfortable with theoretical safety concerns during an advisory committee meeting considering the risks vs. benefits of what would be the first gene therapy for the treatment of sickle cell disease.

Life expectancy for individuals with sickle cell disease has increased by a decade since 2008, according to a study conducted by Epic Research.

Hemophilia death rates among men in the United States improved between 1999 and 2020, according to study results.

The National Academy of Medicine announced the election of 90 regular members and 10 international members.

The FDA announced several regulatory actions.

Relative risk for venous thromboembolism appeared high among patients with COVID-19 and cancer who received specific cancer treatments, according to study results published in JAMA Oncology.

Referral to diagnostic imaging decreased with use of an ultrasound protocol in patients with suspected pulmonary embolism, according to a presentation at the European Respiratory Society International Congress.